Recombinant Human Transmembrane and ubiquitin-like domain-containing protein 1 (TMUB1)

What is the molecular structure of TMUB1 and how is it organized?

TMUB1 (also known as HOPS - Hepatocyte Odd Protein Shuttling) is a 245-amino acid protein characterized by a nuclear export signal (NES) at the amino-terminal and a ubiquitin-like region (UBL; 121–175 aa) . The protein structure includes three key components:

• An N-terminal domain containing a transmembrane structural domain

• A central ubiquitin-like domain

• A C-terminal region containing two transmembrane structures

TMUB1 is a transmembrane protein that shuttles between the nucleus and cytoplasm, potentially transmitting biological signals through this mechanism . The gene encoding TMUB1 is located on chromosome 7 in humans and at the 4q11 position on chromosome 4 in rats .

How is TMUB1 typically expressed across different tissues and conditions?

TMUB1 is ubiquitously expressed, with significant presence in regenerating liver tissue . Expression analysis has revealed:

• TMUB1 mRNA levels are increased in 17 cancer groups and 21 different cancer types according to TCGA database analysis

• There are differential expression patterns in cancerous tissues compared to adjacent normal tissues, though with some contradictions across cancer types

• Expression levels don't change significantly following LPS treatment, suggesting its regulation occurs primarily at the post-translational level rather than transcriptional level

How does TMUB1 influence cell cycle regulation and proliferation?

TMUB1 functions as a negative regulator of cell proliferation, particularly in hepatocytes. Key experimental findings show:

• TMUB1 overexpression leads to G0/G1 cell cycle arrest, while knockdown promotes entry into S phase

• EdU and CCK-8 assays demonstrate that TMUB1 overexpression significantly inhibits cell proliferation rates in BRL-3A cells

• TMUB1 directly interacts with cyclin A2 throughout multiple cell cycle phases (G1, S, and M), potentially influencing both G1/S transition and M phase progression

These effects are mediated through interactions with cell cycle regulatory proteins, particularly cyclins .

What role does TMUB1 play in protein degradation and ubiquitination processes?

As a ubiquitin-like protein, TMUB1 participates in several protein degradation and post-translational modification pathways:

• TMUB1 is involved in the endoplasmic reticulum-associated protein degradation (ERAD) pathway

• It mediates ubiquitylation and degradation of HMG-CoA reductase HMGCR by bridging SPFH2 to the membrane-bound ubiquitin ligase gp78 in ER membranes

• Interestingly, TMUB1 appears to inhibit degradation of cyclin A2 and B1, suggesting context-dependent roles in protein stability regulation

• It competes with HUWE1 (an E3 ubiquitin ligase) to interact with PD-L1, inhibiting its polyubiquitination at K281 in the endoplasmic reticulum

These findings point to TMUB1 as a multifunctional regulator of protein stability, acting as both a facilitator and inhibitor of protein degradation depending on its binding partners and cellular context.

How does TMUB1 expression correlate with cancer progression and prognosis?

The relationship between TMUB1 and cancer appears complex and potentially cancer-type dependent:

This apparent contradiction between increased expression in some cancers and decreased expression in others suggests tissue-specific functions and regulatory mechanisms.

What experimental evidence demonstrates TMUB1's role in tumor suppression?

Several experimental approaches have demonstrated TMUB1's tumor-suppressive functions:

• Xenograft models show that TMUB1 overexpression significantly reduces tumor growth in vivo

• Cell experiments confirm that TMUB1 overexpression suppresses HCC cell proliferation

• Flow cytometry analysis reveals that TMUB1 can promote cell apoptosis

• Mechanistically, TMUB1 overexpression arrests the cell cycle in G0/G1 phase, preventing cancer cell proliferation

Furthermore, TMUB1 interacts with nucleophosmin (NPM) and p19 Arf, resulting in proper control of p19 Arf stability and localization, which provides new mechanistic insight into how TMUB1 opposes cell proliferation .

How does TMUB1 influence immune checkpoint molecules and anti-tumor immunity?

TMUB1 has been identified as a critical modulator of PD-L1 post-translational modifications in tumor cells, directly impacting immune evasion mechanisms:

• TMUB1 competes with HUWE1 (E3 ubiquitin ligase) to interact with PD-L1 and inhibit its polyubiquitination at K281 in the endoplasmic reticulum

• It enhances PD-L1 N-glycosylation and stability by recruiting STT3A, thereby promoting PD-L1 maturation and tumor immune evasion

• TMUB1 protein levels correlate with PD-L1 expression in human tumor tissue, with high expression associated with poor patient survival rates

• A synthetic peptide engineered to compete with TMUB1 significantly promotes antitumor immunity and suppresses tumor growth in mice models

These findings position TMUB1 as a potential immunotherapeutic target in cancer treatment.

What is TMUB1's role in inflammatory signaling pathways?

TMUB1 significantly influences inflammatory responses through the NF-κB signaling pathway:

• TMUB1 enhances NF-κB activation leading to increased transcription of inflammatory mediators by reducing IκBα stability

• This effect is mediated by direct TMUB1 binding to the E3 ubiquitin ligase TRAF6, which lessens TRAF6 stability, ultimately leading to increased IKK complex activation

• Cells from TMUB1 knockout mice (Hops−/−) show reduced expression of pro-inflammatory genes including Il-6, Il-1β, and Tnfα after LPS stimulation

• TMUB1 specifically enhances p65-mediated transcriptional activity, leading to increased expression of pro-inflammatory cytokines, chemokines, and adhesion molecules

Interestingly, TMUB1 appears to selectively influence inflammatory NF-κB target genes without affecting anti-apoptotic or pro-apoptotic NF-κB targets, suggesting pathway-specific regulation .

What are the most effective experimental approaches for studying TMUB1 function?

Based on published research, several effective methodologies have been established:

• Gene Manipulation Techniques:

  • Lentiviral vectors for stable overexpression or knockdown in cell lines

  • CRISPR/Cas9 for generating knockout models (Hops−/− mice)

• Protein Interaction Studies:

  • Co-immunoprecipitation (CoIP) to identify binding partners

  • Mass spectrometry (MS) for identifying Tmub1-binding proteins

  • GST pull-down assays for confirming direct protein interactions

• Functional Assays:

  • EdU and CCK-8 assays for cell proliferation analysis

  • Flow cytometry for cell cycle analysis and apoptosis detection

  • Luciferase reporter assays for studying transcriptional activation

  • Chromatin immunoprecipitation (ChIP) for analyzing histone modifications

• In Vivo Models:

  • Xenograft tumor models in nude mice

  • Transgenic mouse models (Hops−/− mice)

How can researchers overcome challenges in TMUB1 purification and activity assays?

Purification and activity assessment of TMUB1 presents several challenges due to its transmembrane nature and nuclear-cytoplasmic shuttling properties. Researchers should consider:

• Protein Extraction:

  • Use specialized cell lysis buffers containing protease inhibitor cocktail and phosphatase inhibitor cocktail

  • For membrane-bound TMUB1, consider detergent-based extraction methods

• Activity Assessment:

  • Cell cycle synchronization methods using nocodazole (330 nM for 18h) to study phase-specific interactions

  • Time-course experiments following cell cycle release to monitor dynamic interactions

• Localization Studies:

  • Subcellular fractionation to separate nuclear, cytoplasmic, and membrane fractions

  • Immunofluorescence microscopy to track shuttling between compartments

• Recombinant Protein Production:

  • Consider expressing domains separately (particularly the ubiquitin-like domain) for functional studies

  • Use mammalian expression systems rather than bacterial systems to ensure proper post-translational modifications

How might TMUB1 be targeted therapeutically in cancer and immune disorders?

Recent research suggests several potential therapeutic approaches:

• Peptide-Based Interventions:

  • A synthetic peptide engineered to compete with TMUB1 has been shown to promote antitumor immunity and suppress tumor growth in mice models

  • This peptide targets the interaction between TMUB1 and PD-L1, potentially enhancing immune checkpoint blockade therapies

• Combined Immunotherapy Approaches:

  • TMUB1 inhibition could potentially sensitize tumors to existing PD-1/PD-L1 inhibitors

  • Combination therapies targeting both TMUB1 and other immune checkpoint molecules might overcome resistance mechanisms

• Anti-Inflammatory Applications:

  • Given TMUB1's role in NF-κB signaling, inhibitors might have applications in inflammatory conditions

  • The TMUB1-TRAF6 interaction represents a potential target for anti-inflammatory drug development

What current controversies or contradictions exist in TMUB1 research?

Several contradictions and open questions remain in TMUB1 research:

• Cancer-Type Specific Effects:

  • TMUB1 appears upregulated in some cancers but downregulated in others (e.g., higher mRNA levels in 17 cancer groups according to TCGA but lower expression in HCC )

  • This suggests context-dependent functions that require further investigation

• Dual Roles in Protein Stability:

  • TMUB1 promotes ubiquitylation and degradation of some proteins (HMGCR) while inhibiting degradation of others (cyclin A2, B1, PD-L1)

  • The molecular basis for these opposing functions remains unclear

• Cell Cycle Regulation:

  • TMUB1 appears to both inhibit cell proliferation and interact with cyclins essential for cell cycle progression

  • The precise mechanisms integrating these seemingly contradictory functions need clarification

• Therapeutic Potential:

  • Whether TMUB1 inhibition would be beneficial or harmful depends on cancer type and context

  • More research is needed to identify biomarkers predicting response to TMUB1-targeted therapies

What emerging areas of TMUB1 research warrant further investigation?

Several promising research directions emerge from current knowledge:

• Structural Biology:

  • Detailed structural analysis of TMUB1's domains and their interactions with binding partners

  • Crystal structure determination of TMUB1-PD-L1 and TMUB1-cyclin A2 complexes

• Systems Biology Approaches:

  • Comprehensive interactome mapping to identify the complete network of TMUB1 interactions

  • Integration of genomic, transcriptomic, and proteomic data to understand context-dependent functions

• Translational Applications:

  • Development of small-molecule inhibitors targeting specific TMUB1 interactions

  • Biomarker studies to identify patient populations likely to benefit from TMUB1-targeted therapies

• Regulatory Mechanisms:

  • Investigation of how TMUB1 shuttling between cellular compartments is regulated

  • Identification of post-translational modifications that affect TMUB1 function

• Tissue-Specific Functions:

  • Comparative studies across different tissues to understand the basis for contradictory expression patterns in different cancers

  • Development of tissue-specific conditional knockout models

How can understanding TMUB1's role in cholesterol trafficking inform metabolic disease research?

Recent findings link TMUB1 to cholesterol metabolism through interactions with ERLIN scaffolds:

• ERLIN scaffolds mediate interaction between TMUB1 and RNF170

• This complex plays a role in limiting cholesterol esterification, thereby favoring cholesterol transport from the ER to the Golgi apparatus

• These interactions influence Golgi morphology and the secretory pathway

This emerging area connects TMUB1 to metabolic processes and opens potential avenues for investigation in metabolic disorders, particularly those involving lipid metabolism and trafficking.